NCT06722170View on ClinicalTrials.gov

A Study of EH002 Gene Therapy for Otoferlin Gene Mutation-mediated Hearing Loss

NARecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 22, 2024

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2029

Conditions
DFNB9Congenital Hearing LossHearing Loss, Sensorineural
Interventions
GENETIC

EH002 administration

EH002 was administered into one or both ears via intracochlear injection.

Trial Locations (2)

200031

RECRUITING

Eye & ENT Hospital of Fudan University, Shanghai

Unknown

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Yilai Shu

OTHER